Cargando…

“De Novo” Psoriasis and Relapse of Psoriasis Induced by Dupilumab: Three New Cases and Review of the Literature

Atopic dermatitis and psoriasis are traditionally considered diseases that cannot coexist, since they are described as the result of the activation of opposing inflammatory pathways. However, this belief has been debunked, and numerous cases of psoriasis induced by dupilumab, a biologic treatment fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Trave, Ilaria, Salvi, Ilaria, Burlando, Martina, Cozzani, Emanuele, Parodi, Aurora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573833/
https://www.ncbi.nlm.nih.gov/pubmed/37834935
http://dx.doi.org/10.3390/jcm12196291
_version_ 1785120552740978688
author Trave, Ilaria
Salvi, Ilaria
Burlando, Martina
Cozzani, Emanuele
Parodi, Aurora
author_facet Trave, Ilaria
Salvi, Ilaria
Burlando, Martina
Cozzani, Emanuele
Parodi, Aurora
author_sort Trave, Ilaria
collection PubMed
description Atopic dermatitis and psoriasis are traditionally considered diseases that cannot coexist, since they are described as the result of the activation of opposing inflammatory pathways. However, this belief has been debunked, and numerous cases of psoriasis induced by dupilumab, a biologic treatment for atopic dermatitis, have been reported. We report three cases of dupilumab-induced psoriasis and we present a literature review including cases of “de novo” psoriasis and of the relapse of psoriasis that occurred during treatment with dupilumab. In total, 39 publications met the inclusion criteria, including 112 AD patients, 101 of whom developed “de novo” psoriasis, and 11 with a flare of pre-existent psoriasis. In the first group, patients more frequently developed plaque psoriasis on the scalp and extremities, after an average latency period from the initiation of dupilumab of 5 months. In the second group, the incidence of dupilumab-induced relapses of psoriasis was 43%, after an average of 4 months since the first administration. The most common psoriasis type was plaque psoriasis, with the involvement of the scalp and upper extremities. Dupilumab was interrupted in 38% of patients with “de novo” psoriasis and in 50% of relapsed patients, leading, in most cases, to an improvement of psoriasis. In conclusion, atopic dermatitis and psoriasis can definitely co-exist, and biologic drugs used to treat the former can promote the latter. It is thus crucial to perform a careful personal and familiar anamnesis before prescribing any biologic treatment. Moreover, a study of cytokine expression and blood proteomic markers could be considered in these patients.
format Online
Article
Text
id pubmed-10573833
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105738332023-10-14 “De Novo” Psoriasis and Relapse of Psoriasis Induced by Dupilumab: Three New Cases and Review of the Literature Trave, Ilaria Salvi, Ilaria Burlando, Martina Cozzani, Emanuele Parodi, Aurora J Clin Med Review Atopic dermatitis and psoriasis are traditionally considered diseases that cannot coexist, since they are described as the result of the activation of opposing inflammatory pathways. However, this belief has been debunked, and numerous cases of psoriasis induced by dupilumab, a biologic treatment for atopic dermatitis, have been reported. We report three cases of dupilumab-induced psoriasis and we present a literature review including cases of “de novo” psoriasis and of the relapse of psoriasis that occurred during treatment with dupilumab. In total, 39 publications met the inclusion criteria, including 112 AD patients, 101 of whom developed “de novo” psoriasis, and 11 with a flare of pre-existent psoriasis. In the first group, patients more frequently developed plaque psoriasis on the scalp and extremities, after an average latency period from the initiation of dupilumab of 5 months. In the second group, the incidence of dupilumab-induced relapses of psoriasis was 43%, after an average of 4 months since the first administration. The most common psoriasis type was plaque psoriasis, with the involvement of the scalp and upper extremities. Dupilumab was interrupted in 38% of patients with “de novo” psoriasis and in 50% of relapsed patients, leading, in most cases, to an improvement of psoriasis. In conclusion, atopic dermatitis and psoriasis can definitely co-exist, and biologic drugs used to treat the former can promote the latter. It is thus crucial to perform a careful personal and familiar anamnesis before prescribing any biologic treatment. Moreover, a study of cytokine expression and blood proteomic markers could be considered in these patients. MDPI 2023-09-29 /pmc/articles/PMC10573833/ /pubmed/37834935 http://dx.doi.org/10.3390/jcm12196291 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Trave, Ilaria
Salvi, Ilaria
Burlando, Martina
Cozzani, Emanuele
Parodi, Aurora
“De Novo” Psoriasis and Relapse of Psoriasis Induced by Dupilumab: Three New Cases and Review of the Literature
title “De Novo” Psoriasis and Relapse of Psoriasis Induced by Dupilumab: Three New Cases and Review of the Literature
title_full “De Novo” Psoriasis and Relapse of Psoriasis Induced by Dupilumab: Three New Cases and Review of the Literature
title_fullStr “De Novo” Psoriasis and Relapse of Psoriasis Induced by Dupilumab: Three New Cases and Review of the Literature
title_full_unstemmed “De Novo” Psoriasis and Relapse of Psoriasis Induced by Dupilumab: Three New Cases and Review of the Literature
title_short “De Novo” Psoriasis and Relapse of Psoriasis Induced by Dupilumab: Three New Cases and Review of the Literature
title_sort “de novo” psoriasis and relapse of psoriasis induced by dupilumab: three new cases and review of the literature
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573833/
https://www.ncbi.nlm.nih.gov/pubmed/37834935
http://dx.doi.org/10.3390/jcm12196291
work_keys_str_mv AT traveilaria denovopsoriasisandrelapseofpsoriasisinducedbydupilumabthreenewcasesandreviewoftheliterature
AT salviilaria denovopsoriasisandrelapseofpsoriasisinducedbydupilumabthreenewcasesandreviewoftheliterature
AT burlandomartina denovopsoriasisandrelapseofpsoriasisinducedbydupilumabthreenewcasesandreviewoftheliterature
AT cozzaniemanuele denovopsoriasisandrelapseofpsoriasisinducedbydupilumabthreenewcasesandreviewoftheliterature
AT parodiaurora denovopsoriasisandrelapseofpsoriasisinducedbydupilumabthreenewcasesandreviewoftheliterature